Sign Out
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
For trial results with respect to cardiovascular risk reduction, obesity-related heart failure, and populations studied, see Pharmacology: Pharmacodynamics under Actions.
Adolescents (≥12 years): Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity* and body weight above 60 kg.
Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.
*Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 10).
Click on icon to see table/diagram/imageLimitation of Use: Wegovy contains semaglutide and should not be co-administered with other semaglutide containing products or with any other GLP-1 receptor agonist.
The safety and effectiveness of Wegovy in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
Wegovy has not been studied in patients with a history of pancreatitis (see Precautions).
Adolescents (≥12 years): The safety and efficacy of semaglutide in prepubertal adolescents (Tanner stage 1) have not been established.
Lanjutkan dengan Google